By Kevin Truong, MedCity News | May 21, 2019
The company just announced strategic alliances with Novartis, Otsuka, Pfizer and Sanofi to develop new clinical research programs utilizing the Project Baseline platform across therapeutic areas ranging from cardiovascular disease to oncology to mental health.
Alphabet’s Verily life science division launched its Project Baseline back in 2017 with the ambition to make it easier for individuals to get involved in the clinical trial process and build a “comprehensive map of human health.”
In order to enable this goal, Verily has developed new tools meant to make it faster and easier to conduct research in real-world settings that garners high quality data.
While the program started with the support of academic institutions like Duke and Stanford Universities, Verily has been signing up a host of new industry partners to build its clinical research ecosystem.
Case in point, the company just announced strategic alliances with Novartis, Otsuka, Pfizer and Sanofi to develop new clinical research programs utilizing the Project Baseline platform across therapeutic areas ranging from cardiovascular disease to oncology to mental health.
“Evidence generation through research is the backbone of improving health outcomes. We need to be inclusive and encourage diversity in research to truly understand health and disease, and to provide meaningful insights about new medicines, medical devices and digital health solutions,” Verily Chief Medical and Scientific Officer Jessica Mega said in a statement.
“Novartis, Otsuka, Pfizer and Sanofi have been early adopters of advanced technology and digital tools to improve clinical research operations, and together we’re taking another step towards making research accessible and generating evidence to inform better treatments and care.”